CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
High ImpactOriginal article

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

Positive
AI Analysis

Summary

Argenx announced a $2.2B acquisition of Forte to add a CD122-targeted immune drug to its pipeline, leveraging an approach gaining traction among multiple developers.

Outcome Details

$2.2B acquisition deal for CD122-targeted immune drug

Importance:8/10
Sentiment:
0.70
acquisitionM&AimmunologyCD122drug development
Related Companies

Read the original article

Published by BioPharma Dive on July 27, 2026 3:46 PM

Read Original